Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ingersoll Rand (IR) vs Eli Lilly And Co (LLY) Price & Performance

Ingersoll RandTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Ingersoll Rand vs Eli Lilly And Co — how do they compare? Ingersoll Rand trades at $78.13 (market cap $30.26B), while Eli Lilly And Co trades at $1,171.11 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 34.4× Ingersoll Rand's market cap, and Eli Lilly And Co pays the higher dividend (0.59%). Which is the better fit depends on your goals — on Pluang, investors hold Ingersoll Rand for 7 Days and Eli Lilly And Co for 93 Days on average.

IRLLY
Market Cap
$30.26B$1.04T
Volume
4,017,6223,064,878
Sector
IndustrialsHealth
52-Week High
$98.76$1.28K
52-Week Low
$68.54$799.57
Typical Hold Time
7 Days93 Days
Enterprise Value
$33.92B$1.09T
Dividend Yield
0.1%0.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ingersoll Rand

No Aura AI signal available yet.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.

Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IR

No sentiment data available yet.

LLY
69% Buy31% Sell
Avg holding period · 93 Days

Top news

Latest headlines on both assets

About Ingersoll Rand

Ingersoll Rand develops industrial technologies for creating and managing flow, pressure, and motion. Its portfolio includes compressors, pumps, vacuum systems, and other equipment used across industrial markets.

Read more on IR →

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY →